Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 7/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947904 | 0.84 | IL4I1 (0.46) | IL4I1TP53CD38LMNAPDE4A | |
| SCHEMBL30948025 | 0.81 | IL4I1 (0.46) | IL4I1TP53CD38HCRTR1HCRTR2 | |
| SCHEMBL27162868 | 0.80 | IL4I1 (0.49) | IL4I1TP53LMNAHCRTR1HCRTR2 | |
| SCHEMBL30948302 | 0.80 | TP53 (0.43) | IL4I1TP53LMNA | |
| SCHEMBL30948265 | 0.79 | IL4I1 (0.74) | IL4I1TP53LMNAPDE4A | |
| SCHEMBL27163578 | 0.78 | IL4I1 (0.51) | IL4I1TP53LMNA | |
| SCHEMBL30948250 | 0.78 | IL4I1 (0.59) | IL4I1TP53CD38LMNA | |
| SCHEMBL30948258 | 0.77 | IL4I1 (0.74) | IL4I1TP53LMNAPDE4A | |
| SCHEMBL27163414 | 0.76 | IL4I1 (0.57) | IL4I1TP53LMNAPDE4A | |
| SCHEMBL27163516 | 0.75 | IL4I1 (0.48) | IL4I1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885TP53 1444/4885CD38 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.